AlivaMab Discovery Services
  • What We Do
    • Antibody Discovery
    • Antibody Engineering
  • Technologies
    • AlivaMab® Mouse
    • AMMPD Immunizations
    • Fit-for-Purpose Screening
    • Immune Repertoire Display
    • Bispecific Formats
  • Team
    • Leadership
    • Board of Directors
  • Resources
    • News
    • Case Studies
    • Webinars & Presentations
    • Upcoming Events
    • Features & Interviews
  • Careers
  • Company
    • About Us
    • Contact

Join our team in creating a healthier world through partnerships that bring better medicines to patients faster

  • What We Do
    • Antibody Discovery
    • Antibody Engineering
  • Technologies
    • AlivaMab® Mouse
    • AMMPD Immunizations
    • Fit-for-Purpose Screening
    • Immune Repertoire Display
    • Bispecific Formats
  • Team
    • Leadership
    • Board of Directors
  • Resources
    • News
    • Case Studies
    • Webinars & Presentations
    • Upcoming Events
    • Features & Interviews
  • Careers
  • Company
    • About Us
    • Contact
  • What We Do
    • Antibody Discovery
    • Antibody Engineering
  • Technologies
    • AlivaMab® Mouse
    • AMMPD Immunizations
    • Fit-for-Purpose Screening
    • Immune Repertoire Display
    • Bispecific Formats
  • Team
    • Leadership
    • Board of Directors
  • Resources
    • News
    • Case Studies
    • Webinars & Presentations
    • Upcoming Events
    • Features & Interviews
  • Careers
  • Company
    • About Us
    • Contact

Team

Our team is dedicated to a healthier world through partnerships that bring better medicines to patients faster.

Leadership

Larry Green, Ph.D.

Larry Green, Ph.D. >

Founder and CEO

John “Lippy” Lippincott, Ph.D.

John “Lippy” Lippincott, Ph.D. >

VP of Research

Jane Seagal, PhD

Jane Seagal, PhD >

Crystal Bantados, PMP

Crystal Bantados, PMP >

Jennifer Cassidy

Jennifer Cassidy >

Board of Directors

Larry Green, PhD

Larry Green, PhD >

Founder and Board Member

Cameron Wheeler, Ph.D.

Cameron Wheeler, Ph.D. >

Board Member

Adam Grossman

Adam Grossman >

Board Member

Talk with an Expert

    AlivaMab Discovery Services
    • What We Do
    • Technologies
    • Team
    • Resources
    • Careers
    • Company
    • AlivaMab Discovery Services, LLC
    • 10581 Roselle Street, Suite 115
    • San Diego, CA 92121
    • info@alivamab.com
    • 1-858-866-9310
    • Privacy Policy

    © AlivaMab Discovery Services, LLC. All rights reserved.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    AlivaMab Discovery Services
    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Read our full Privacy Policy here.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!

    Larry Green, PhD

    Larry Green, PhD, is a board member of AlivaMab Discovery Services and co-inventor of the AlivaMab® Mouse. He also serves as Chief Executive Officer of Ablexis, LLC. Larry has a quarter century of experience in designing, building, and using antibody drug discovery platforms, which has resulted in seven approved antibody drugs and multiple others in clinical trials. He is an inventor on over 60 US patents covering therapeutic product candidates and immunoglobulin transgenic mice, including the XenoMouse® platform (Abgenix/Amgen) and the AlivaMab Mouse platform (Ablexis), plus dozens of issued patents in other geographies. He has served as a founder of three companies, Abgenix, Inc. (founded 1996, acquired by Amgen, Inc. in 2006), Ablexis, LLC (founded 2009, acquired by Deerfield Management Company in 2018), and AlivaMab Discovery Services, LLC (founded 2018). He holds a PhD in molecular and cellular biology from the University of Wisconsin-Madison and a BSc with honors in chemistry from the University of Kentucky.

    Larry Green, Ph.D.

    Larry Green, Ph.D., is the Executive Chairman of AlivaMab Discovery Services and co-inventor of the AlivaMab® Mouse. He also serves as Chief Executive Officer of Ablexis, LLC. Larry has a quarter century of experience in designing, building and using antibody drug discovery platforms, which has resulted in seven approved antibody drugs and multiple others in clinical trials. He is an inventor on over 60 US patents covering therapeutic product candidates and immunoglobulin transgenic mice, including the XenoMouse® platform (Abgenix/Amgen) and the AlivaMab Mouse platform (Ablexis), plus dozens of issued patents in other geographies. He has served as a founder of three companies, Abgenix, Inc. (founded 1996, acquired by Amgen, Inc. in 2006), Ablexis, LLC (founded 2009, acquired by Deerfield Management Company in 2018), and AlivaMab Discovery Services, LLC (founded 2018). He holds a Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and a B.Sc. with honors in Chemistry from the University of Kentucky.

    John “Lippy” Lippincott, Ph.D.

    LinkedIn Logo

    Lippy is Vice President of Research at AlivaMab Discovery Services. He has over two decades of experience in the generation and characterization of antibodies from in vivo systems.

    Prior to joining AlivaMab Discovery Services, Lippy established and led the hybridoma group at Pfizer’s San Diego site, where he was project leader for internal and co-development therapeutic discovery projects. At Igenica, he led the successful importation of a novel in vivo discovery platform and created a high-throughput system for hybridoma generation and screening, and led other processes required for identifying lead therapeutic candidates. Serving in the role of Vice President, Antibody Discovery at LakePharma, Lippy built and led the team responsible for providing antibody discovery services to clients. Lippy received his Ph.D. from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.

    Jane Seagal, PhD

    LinkedIn Logo

    Jane is Vice President of Antibody Discovery at AlivaMab Discovery Services. She has over a decade of experience in antibody discovery for biologics drug development using in vivo approaches.

    Prior to joining AlivaMab Discovery Services, Jane established and led the In Vivo Antibody Discovery and Antibody Sequencing teams at AbbVie, where she also headed a cross-functional team of scientists responsible for biologics discovery and screening funnel strategies. Jane introduced and implemented multiple technology platforms including hybridoma automation, novel immunization protocols, digital hybridoma concept, and direct antibody cloning from human patient samples. These technological advances had a direct impact on the biologics pipeline, helping scientists approach targets once thought undruggable by biologics and resulting in several current clinical candidate molecules. Jane has led projects across diverse therapeutic areas including oncology, immunology, and virology.

    Jane earned her PhD in immunology at the Technion—Israel Institute of Technology in Haifa, Israel and completed post-doctoral research at Harvard Medical School.

    Crystal Bantados, PMP

    LinkedIn Logo

    Crystal has more than 14 years of industry experience in drug safety and medical devices and is responsible for project and alliance management at the company. Prior to joining AlivaMab Discovery Services, she was at Truvian Sciences and Aviva Biosciences where she played a key role in driving projects forward and maintaining strategic partnerships.

    Crystal earned her BS in chemical engineering from the University of California, San Diego and holds a Project Management Professional (PMP) certification from the Project Management Institute (PMI).

    Jennifer Cassidy

    LinkedIn Logo

    Jennifer has over 20 years of progressive human resources experience within global, multi-state, and multi-site organizations in the life sciences and biotechnology, regenerative medicine, medical device, pharmaceutical, technology, manufacturing, and telecommunications industries.

    Prior to joining AlivaMab Discovery Services, Jennifer worked at WuXi AppTec (a global pharmaceutical, biopharmaceutical and medical device company) and Veracyte (a global diagnostics company) where she played a key role as the Human Resources Leader for multiple sites. Jennifer has vast experience partnering with high-growth businesses to develop outstanding cultures, provide strategic HR support, and identify solutions that maximize both company and employee success.

    Jennifer earned her BS in human services management from the University of Phoenix and holds a Human Resources Management Certification from University of California, San Diego.

    Cameron Wheeler, Ph.D.

    Cameron Wheeler, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals, Inc. and a Senior Associate at Third Rock Ventures, LLC. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

    Adam Grossman

    Adam Grossman is a Partner on the Healthcare Services group at Deerfield and joined the Firm in 2017 to work on structured transactions in the healthcare services and healthcare information technology space. Prior to Deerfield, Mr. Grossman worked at The Advisory Board Company, where he spent approximately five years as Senior Vice President, Corporate Development and Operations. Prior to The Advisory Board Company, he spent four years at Health Evolution Partners, a leading healthcare-focused private equity firm based in San Francisco. Mr. Grossman also spent more than five years at Aetna where he worked on enterprise strategy and founded its internal venture fund. Mr. Grossman holds an A.B. in Government from Dartmouth College and an M.B.A. from Harvard Business School.

    James Graziano, Ph.D.

    LinkedIn Logo

    James has twenty-five years of operations management experience spanning a range of technical industries and applications from nuclear-powered propulsion systems and industrial chemical processing to biological research laboratories. Additionally, James has fifteen years of protein engineering and bioprocessing experience focused on recombinant antibodies for drug screening and development.

    James joined Sevion Therapeutics as Chief Technology Officer in 2014 upon the merger of Fabrus and Senesco, where he was responsible for managing the corporate and research operations for a publicly-traded company as well as mammalian cell line development and recombinant protein production. Prior to his time a Sevion, he managed corporate and research operations for Fabrus starting in 2007 as the Chief Operating Officer and co-founder.

    James received his Ph.D. from The Scripps Research Institute working jointly with the Genomics Institute of the Novartis Research Foundation and was a staff scientist at Kythera Biopharmaceuticals, Inc.  Prior to receiving his doctorate, James was a qualified and decorated nuclear propulsion plant mechanic and work center supervisor in the U.S. Navy on board both USS Enterprise and USS Texas.

    Dana Duey

    LinkedIn Logo

    Dana brings a combined twelve years of experience in therapeutic antibody development at both large and small biopharmaceutical companies.  Dana was a founding member of the Ablexis research group responsible for creating the data package for validating the AlivaMab Mouse.  He was instrumental in the execution of the recovery and screening workflows that yielded therapeutic-quality AlivaMab antibodies.

    Dana was part of the hybridoma group at Pfizer, Inc. in the metabolic disease group at Pfizer CovX and a member of Pfizer Exploratory Technologies exploring cancer stem cells.   At Igenica, Inc., Dana was a founding member of the hybridoma group, establishing the hybridoma platform and assay screening methods for generating their therapeutic antibody candidates. Dana served as a scientist in the antibody discovery group at NGM Biopharmaceuticals, Inc., where he worked on diverse targets utilizing the latest tools, methods and technologies available in antibody development.

    Dana received his B.S. in pharmacology from the University of California, Santa Barbara.

    Jacek Ostrowski, Ph.D.

    LinkedIn Logo

    Jacek brings more than fourteen years of experience largely focused on protein chemistry and therapeutic antibody discovery and development to his role as the Associate Director of Protein Sciences.  He has broad and deep experience in the analytical characterization of antibodies in addition to expression and purification.  Jacek has led antibody drug conjugate programs investigating new chemistries and new payloads with lower off target toxicities.  He has directed development programs assessing the developability and formulation in therapeutic antibodies including the initiation and direction of cGMP manufacturing campaigns.

    Jacek comes to AlivaMab having helped launch early-stage biotechnology and biotherapeutic companies such as Phanes Therapeutics, MabVax Therapeutices, Sevion Therapeutics, and Chimeros.  Jacek received his BS in chemistry from Saint Mary’s College of California and his Ph.D. in material chemistry from the University of California Santa Barbara.

    Aleksandra “Sanja” Marinkovic-Petrovic

    LinkedIn Logo

    Aleksandra has over 15 years of experience in biotech industry, including immunology, tissue culture, protein purification and analytics, virology, molecular biology, and in-vivo work. At AlivaMab Discovery Services, she supports antibody generation as a member of antibody discovery team. In addition to this, Aleksandra is responsible for the vivarium and lab management.

    Prior to joining ADS , as Senior Research Associate at PaxVax Inc. she planned and executed virus neutralization assays, VLP production and analysis in bioreactors, planned and supported in-vivo testing of vaccine candidates, assessed immune response and performed various molecular biology techniques. As Associate Scientist at MabVax Therapeutics, she supported mAb discovery platform using B cells derived from vaccinated cancer patients and identification of lead drug candidates. At The Scripps Research Institute, as Research Assistant II, Aleksandra worked on HIV entry and large molecule inhibitors, and performed in-vivo work with human stem cells. At Pharmexa-Epimmune, as Senior Research Assistant, she worked on evaluation of DNA vaccine candidates for various infectious diseases, protein purification and analysis, and performed in-vivo work.

    Aleksandra studied Microbiology and Veterinary Medicine at University of Belgrade, Serbia.

    Ritsuko Sawada, Ph.D.

    Ritsuko has more than fifteen years of experience in discovery and development of therapeutic human monoclonal antibodies including expression, validation, affinity maturation and cell line development.

    Prior to joining AlivaMab Discovery Services, Ritsuko led the antibody discovery team at MabVax Therapeutics, where she established the anti-tumor associated carbohydrate antigen (TACA) mAb discovery platform using B cells derived from vaccinated cancer patients and identified lead drug candidates.  As a staff scientist at Avanir Pharmaceuticals, she oversaw the antibody group and improved the human mAb generation platform using SCID mice against infectious disease targets.

    Ritsuko received her Ph.D. in Molecular and Cellular Biology from the Ochanomizu University in Tokyo and did postdoctoral research at the University of California at San Diego.

    Crystal Bantados

    LinkedIn Logo

    Crystal has more than 14 years of industry experience in drug safety and medical devices and is responsible for project and alliance management at the company. Prior to joining AlivaMab Discovery Services, she was at Truvian Sciences and Aviva Biosciences where she played a key role in driving projects forward and maintaining strategic partnerships.

    Crystal earned her BS in Chemical Engineering from the University of California at San Diego and holds a Project Management Professional (PMP) certification from the Project Management Institute (PMI).

    Mohammad Abu Odeh, Ph.D.

    LinkedIn Logo

    At AlivaMab Discovery Services, Mohammad is part of the antibody discovery team supporting antibody generation. Prior to joining ADS, Mohammad was a postdoctoral researcher at the University of California, San Diego where he discovered the mechanism of action of a promising drug for the treatment of diabetes and obesity. His background and experience includes formulation of drugs, animal dosing, lentiviral transduction (protein silencing by shRNA) of normal and tumor cell lines, blood/tissue sample collection, and sample preparation for analysis.

    Mohammad received his Ph.D. in cell biology, immunology, and cancer research from the Hebrew university of Jerusalem.

    Stacey Borders

    LinkedIn Logo

    Stacey is a Market Development Partner at AlivaMab Discovery Services. She has 10+ years of experience in the biotech industry where her scope has included event management, product management, digital marketing, and business development. In her most recent position as the Director of Marketing at Tonbo Biosciences, she helped the company steadily grow market share as she oversaw the marketing, business development, and sales teams. Stacey received her Bachelor of Business Administration from the University of San Diego.

    Travis Grant

    LinkedIn Logo

    Prior to working at AlivaMab Discovery Services, Travis spent multiple summers working at Pfizer where he worked with mutant KRAS Human Colon Cancer cells lines. In his work, Travis examined MAPK signaling and protein interactions to test for possible alternate signaling pathway routes in traditional MAPK signaling. During his time at Pfizer and Liberty University, Travis became proficient in sterile cell culture techniques and various cellular assays.

    Ali Ataei

    Ali has over five years of experience in the biotech industry, including in protein expression and purification. At AlivaMab Discovery Services, Ali is part of the Protein Sciences team.

    Prior to joining AlivaMab Discovery Services, Ali was a Senior Research Associate at SDBioscience. He was responsible for establishing purification protocols and expression in various cellular systems.

    Ali received his Bachelor of Nutrition from the Science and Research Department at Tehran University.

    Ranveer Jayani

    LinkedIn Logo

    Ranveer is part of the Protein Sciences team at AlivaMab Discovery Services. He is a molecular and cell biologist with expertise in oncology, biochemical assays, epigenetics, transcriptional/translational regulation, NGS, and genomic engineering techniques.  Most recently, Ranveer worked as an Assistant Project Scientist at UC San Diego School of Medicine, where he studied the role of loss of transcription factor binding in regulation of long non-coding RNAs in prostate cancer.

    Ranveer received his Ph.D. in chromatin biology from National Centre for Cell Science, Pune, India.

    Linda Masat, Ph.D.

    LinkedIn Logo

    Linda is Head of European and Strategic Business Development at AlivaMab Discovery Services.

    Linda has over 20 years of experience discovering and developing therapeutic antibodies through scientific innovation, strategic alliances and transactions.

    Prior to joining AlivaMab Discovery Services, Linda was V.P. Business Development at Trianni Inc. At Takeda Pharmaceutical, as Director of Strategic Academic Alliances she established and led collaborations with academic laboratories and early-stage companies. Prior to this role, Dr. Masat led multidisciplinary teams at Takeda, XOMA and Abgenix (now Amgen) in the discovery and preclinical development of biologics. Linda is the inventor of gevokizumab and has 7 issued patents covering the discovery of therapeutic antibodies. Dr. Masat received her Ph.D. in Biochemistry from the University of Urbino, Italy and did her postdoctoral training at the University of California, San Francisco.

    Blisseth Sy

    LinkedIn Logo

    Blisseth has over 15 years of scientific and commercial drug discovery experience, from preclinical R&D to scale-up to manufacturing. Prior to joining Alivamab, she supported business development efforts at Charles River Laboratories for preclinical discovery services. Blisseth received her bachelor’s degree from University of California, Berkeley and her Master of Science from University of California, Davis.